YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in ...

Ascendis Pharma (ASND) has released an update. Ascendis Pharma reported a revenue of €57.8 million in Q3 2024, driven by product launches and ...

Ascendis Pharma (ASND) has released an update. Ascendis Pharma has released its unaudited financial results for the period ending September 30, ...

Ascendis Pharma (ASND) is scheduled to announce Q3 earnings results on Thursday, November 14th, after market close. The ...

Ascendis Pharma (ASND) has released an update. Ascendis Pharma has entered a collaboration with Novo Nordisk to license its ...

Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 ...

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

Wedbush upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports. ASND has been the topic of ...

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of drug-enhancing technology.

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

Cantor Fitzgerald restated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a report published on Monday, Benzinga reports. They currently have a $170.00 ...

Adults with hypoparathyroidism treated with TransCon PTH in the phase 3 PaTHway open-label trial extension demonstrated ...